Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Key Points

• Beth Hecht sold 16,667 shares of Xeris Biopharma on May 1 at an average price of $6.23 under a pre-arranged Rule 10b5-1 plan, trimming her stake by 1.38% to 1,193,173 shares.
• XERS traded up 2.4% to $6.28 and has a market cap of $1.08 billion with a 12‑month range of $4.26–$10.08; the company beat EPS estimates ($0.06 vs. $0.03) but slightly missed revenue, and analysts rate it a "Moderate Buy" with an average target of $10.80.
• Institutional investors have been active, with notable increases from Goldman Sachs, Millennium Management and Royal Bank of Canada, and institutions now own about 42.75% of the stock.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the completion of the sale, the insider directly owned 1,193,173 shares of the company's stock, valued at $7,433,467.79. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $5.99, for a total value of $99,835.33.
• On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $6.25, for a total transaction of $104,168.75.
• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total transaction of $124,169.15.

Xeris Biopharma Stock Up 2.4%

NASDAQ XERS traded up $0.15 on Friday, reaching $6.28. 1,410,871 shares of the stock traded hands, compared to its average volume of 1,852,747. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. The company has a fifty day moving average price of $5.93 and a 200-day moving average price of $7.03. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -627.37 and a beta of 0.77. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.26 and a 12 month high of $10.08.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%. As a group, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

XERS has been the topic of several research analyst reports. Weiss Ratings upgraded Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Wall Street Zen upgraded Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 7th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, Xeris Biopharma currently has an average rating of "Moderate Buy" and an average price target of $10.80.

Institutional Trading of Xeris Biopharma

Several large investors have recently added to or reduced their stakes in XERS. Royal Bank of Canada grew its stake in Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company's stock valued at $1,170,000 after purchasing an additional 198,984 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock valued at $461,000 after purchasing an additional 3,594 shares during the last quarter. Millennium Management LLC grew its stake in Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock valued at $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Caxton Associates LLP purchased a new stake in Xeris Biopharma during the 1st quarter valued at about $170,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.